The 81-Milligram Pill That Just Matched a Blood Thinner After Joint Surgery

Key Takeaway

In a double-blind trial involving 5,429 patients undergoing total hip and knee arthroplasty, low-dose aspirin initiated immediately following surgery proved just as effective as a 5-day rivaroxaban run-in in preventing symptomatic venous thromboembolism (0.48% vs. 0.45%), with no added risk of bleeding. For the vast majority of standard-risk patients, the conventional two-drug transition strategy now appears to be an ingrained clinical ritual rather than a medical necessity.

A Two-Drug Transition at Discharge

On the morning after undergoing total knee arthroplasty, a 68-year-old retired teacher is already ambulating down the hallway alongside her physical therapist, eager to return home. Her discharge paperwork, however, outlines a two-stage regimen: rivaroxaban for the first 5 days, followed by 9 days of aspirin therapy. She finds herself asking the nurse twice to clarify exactly when to discontinue the first medication and transition to the second. For years, this stepwise protocol served as a cautious compromise, born out of concern that aspirin monotherapy during the critical early postoperative days might fail to…